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See Article, pages 1353–1360Following liver injury, hepatic stellate cells (HSCs) lose their
characteristic lipid droplets to differentiate into extracellular
matrix producing myoﬁbroblasts. Activation of HSCs is consid-
ered one of the main mechanisms contributing to the develop-
ment of hepatic ﬁbrosis in chronic liver diseases [1]. Although
several key pathways for HSC activation, such as TGFb and PDGF
have been identiﬁed, there is still a lack of clinically applicable
approaches to target HSCs for anti-ﬁbrotic therapies. Identiﬁca-
tion of additional pathways involved in HSC activation may
reveal more suitable anti-ﬁbrotic targets than those already iden-
tiﬁed. The study by Thoen et al. in this issue of the Journal of
Hepatology investigates the role of autophagy in HSC activation
and the loss of HSC lipid stores, one of the most characteristic fea-
tures of the HSC activation process [2].
Like most biological systems, cells need to degrade many of
their components thus allowing for constant turnover and
renewal of proteins and organelles, and adaptation to changing
conditions. Degradation occurs through two speciﬁc
machineries – the proteasome and the lysosome [3]. The pro-
teasome degrades proteins that are speciﬁcally tagged by mark-
ers such as ubiquitin, allowing this precise proteolytic
machinery to recognize proteins destined for degradation. The
lysosome is able to degrade various cellular components
through different processes termed macroautophagy, micro-
autophagy, and chaperone-mediated autophagy [4]. These three
types of autophagy differ from each other in terms of the deliv-
ery method of the ‘‘cargo’’ to the lysosome, and their selectivity
for speciﬁc types of cargo. The study by Thoen et al. focuses on
macroautophagy, a catabolic process in which the cargo is ﬁrst
sequestered inside double-membrane vesicles called auto-
phagosomes and then fused to lysosomes [4]. After degradation,
resulting amino acids or other small molecules are released
back into the cytoplasm and can be used for various purposes
including energy harvest [4,5]. Accordingly, macroautophagy
(referred hereafter as ‘‘autophagy’’) is increased in nutrient poor
states, or stress conditions [4,5]. Increased autophagy has also
been described in cell death and may, therefore, play a dualJournal of Hepatology 20
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E-mail address: rfs2102@columbia.edu (R.F. Schwabe).role in cell survival depending on conditions and stimuli. How-
ever, in many cases this is probably ‘‘cell death with autophagy
rather than cell death by autophagy’’ [6] suggesting that the
autophagic response is largely a cell-protective response in
mammalian cells. Accordingly, defective autophagy has been
linked to common human diseases, such as neurodegenerative
conditions including Alzheimer’s disease, Parkinson’s disease,
metabolic disorders, such as diabetes and obesity, and aging
[3].
Thoen et al. explore the relationship between autophagy and
HSC activation, and introduce the idea of targeting autophagy
for the prevention of HSC activation [2]. Several key ﬁndings of
the study support the idea that autophagy promotes HSC activa-
tion: (i) Fibrotic livers from CCl4-treated mice displayed
increased expression of LC3-II, one of the proteins involved in
elongation of autophagosomes, and a useful indirect measure of
autophagosomes. (ii) Autophagic ﬂux is increased in mouse HSCs
after in vitro activation as demonstrated by DsRed-GFP-LC3B
transfection. With this method red punctae from DsRed (stable
in an acidic lysosomal milieu) mark autophagolysosomes and
yellow punctae from mixed DsRed, and GFP (whose ﬂuorescence
is quenched in the acidic lysosomal milieu) ﬂuorescence label
autophagosomes. The authors found a signiﬁcant increase in
red punctae during HSC activation indicating increased autopha-
gic ﬂux. (iii) Autophagy inhibitors baﬁlomycin A1, 3-methylade-
nine, and hydroxychloroquine efﬁciently suppress in vitro
activation of mouse and human HSCs as evidenced by decreased
expression of activation makers, such as platelet-derived growth
factor receptor, Acta2, and Col1a1 mRNA expression, and a-SMA
protein. Notably, disrupting baﬁlomycin treatment allowed HSCs
to resume activation suggesting that toxic effects of baﬁlomycin
are unlikely to be involved in the suppression of HSC activation.
Despite the appealing hypothesis and the strong evidence for
autophagy contributing to HSC in vitro activation, the study by
Thoen et al. leaves a number of open questions. One area in which
this study falls short, is the investigation of underlying mecha-
nisms. Thoen et al. observed that baﬁlomycin treated cells had
increased large lipid droplets, which are more characteristic of
quiescent rather than activated HSCs. Additionally, treatment of
HSCs with PDGF induced co-localization of lipid droplets and
LC3-B ﬂuorescence suggesting that autophagy is responsible for
the metabolism lipid droplet metabolism. These ﬁndings are sim-
ilar to observations in hepatocytes where autophagy negatively11 vol. 55 j 1176–1177
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regulates lipid stores through a process called macrolipophagy
[7]. However, there is no solid evidence that the decrease in
HSC lipid droplets promotes their activation in liver ﬁbrosis.
One study addressing this issue found that HSCs that do not con-
tain any lipid droplets do not activate spontaneously nor do they
show increased activation in response to CCl4 treatment or bile
duct ligation [8]. Additionally, mTOR contributes to the activation
of HSCs and promotion of liver ﬁbrosis [9–11] but inhibits
autophagy [12]. The data from Thoen et al. seem to contradict
the HSC-activating yet autophagy-inhibiting effect of mTOR.
Therefore, it would be important to further delineate the relation-
ship between mTOR, autophagy, and HSC activation. A second
concern is the complete reliance of Thoen et al. on chemical
inhibitors of autophagy. It cannot be excluded that these inhibi-
tors exert non-speciﬁc effects and that the observed decrease in
HSC activation is not entirely mediated by autophagy inhibition.
Elegant genetic approaches such as the conditional deletion of
Atg7 have been employed to study autophagy in the liver and
other organs [7], and should be used to conﬁrm pharmacological
approaches. Finally, the study on HSC activation is entirely based
on in vitro models of HSC activation. The only in vivo part of this
study is on whole liver extracts from CCl4-treated mice and lacks
an investigation of autophagy regulation in HSCs and other cell
types in the ﬁbrotic liver. In vitro activation of mouse and human
HSCs differs considerably from in vivo activation due to the
absence of various cell–cell interactions and soluble mediators
that are typically present in the injured liver [13,14]. To exclude
that the observed induction of autophagic ﬂux is merely a result
of cell culture conditions, conﬁrmatory in vivo studies are needed
that compare autophagic ﬂux in quiescent and activated HSCs
directly in the liver, or between HSCs isolated from normal or
ﬁbrotic livers. Along this line, it should be pointed out that the
comparison of autophagic ﬂux in quiescent and culture-activated
HSCs by DsRed and GFP ﬂuorescence is challenging due to differ-
ent time intervals between transfection and analysis under these
conditions.
When considering the potential therapeutic implications of
the study by Thoen et al., one needs not only to consider the often
protective role of autophagy in human physiology and patho-
physiology [3], but also its functions in hepatic cell populations
besides HSCs [15]. In the liver, autophagy appears to predomi-
nantly exert protective functions including the promotion of
hepatic function during aging, protection from hepatocellular
carcinoma, protection from liver disease due to a1-antitrypsin
deﬁciency, and protection from Mallory-Denk body formation
and liver injury in alcoholic liver disease [16–19]. However,
under some conditions the autophagic machinery may also pro-
mote liver disease – e.g. in patients with viral hepatitis where
HBV and HCV hijack this machinery for their own beneﬁt [15].
In conclusion, targeting autophagy for anti-ﬁbrotic therapies is
likely to have broad and many unwanted effects in the liverJournal of Hepatology 2011and other organs, and currently does not appear to be an attrac-
tive target for anti-ﬁbrotic therapies. Further in vitro and in vivo
studies are required to conﬁrm and understand the role and tar-
gets of autophagy in HSCs in the ﬁbrotic liver, and may reveal
novel players in the HSC activation process.References
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